Eton Pharmaceuticals, Inc. Stockholders Equity

Quick Answer

Eton Pharmaceuticals, Inc. reported Stockholders Equity of $26.15 million for fiscal year 2025.

Eton Pharmaceuticals, Inc. Stockholders Equity — Annual History

Fiscal Year Stockholders Equity YoY Change
2025 $26.15M +7.1%
2024 $24.43M +57.8%
2023 $15.48M +18.3%
2022 $13.08M -25.8%
2021 $17.63M +0.0%
2020 $17.63M +67.1%
2019 $10.55M -59.9%
2018 $26.30M +482.6%
2017 -$6.87M

Quarterly Stockholders Equity

Quarter Ending Stockholders Equity YoY QoQ
September 30, 2025 $23.13M +44.7% -3.5%
June 30, 2025 $23.96M +78.0% -2.0%
March 31, 2025 $24.45M +57.8% +0.1%
December 31, 2024 $24.43M +57.8% +52.9%
September 30, 2024 $15.98M -5.4% +18.7%
June 30, 2024 $13.46M -19.5% -13.1%
March 31, 2024 $15.49M +37.8% +0.1%
December 31, 2023 $15.48M +18.3% -8.4%
  • Eton Pharmaceuticals, Inc. showed an increase of +7.1% in Stockholders Equity compared to the prior fiscal year.
  • Over the 2017–2025 period, Eton Pharmaceuticals, Inc.’s stockholders equity has grown by 480.5% (from -$6.87 million to $26.15 million).
  • The most recent figure is from Eton Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 19, 2026.
  • All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.

Last verified:

Leave a Comment